279
An ultra-rare blood disease, very debilitating and which can cause – in severe cases – even death. It is paroxysmal nocturnal hemoglobinuria and now for the patients who suffer from it comes a new possibility of treatment. The Italian Medicines Agency, in fact, has approved ravulizumab which, thanks to its administration every two months, reduces the impact of treatment on patients, improving their quality of life.